公开(公告)号：US20170107294A1

公开(公告)日：2017-04-20

申请号：US15126938

申请日：2014-03-21

Applicant: Nordlandssykehuset HF ,  Norwegian University of Science and Technology CO/ NTNU Technology Transfer AS ,  University of Oslo

Inventor： Terje Espevik ,  Tom Eirik Mollnes ,  Inger Sandlie ,  Corinna Lau ,  Kristin S. Gunnarsen

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  C07K14/765

CPC classification number: C07K16/2896 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K14/765 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2319/31

Abstract: The present invention relates to chimeric anti-CD14 antibodies and methods of using the same. In some embodiments, the present invention relates to the use of chimieric anti-CD 14 antibodies in research, diagnostic, and therapeutic applications. In one embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 1 and a variable heavy chain of SEQ ID NO: 2 (isolated from the hybridoma clone 18D11). In another embodiment, the anti-CD14 antibody has a variable light chain of SEQ ID NO: 3 and a variable heavy chain of SEQ ID NO: 4 (isolated from the hybridoma clone Mil2).